Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor Responses July 18, 2019 - NASDAQ Companies 0 » View More News for July 18, 2019
